The Freedman Lab seeks to understand how microscopic events produce macroscopic organs and disease. Our model is the kidney, a beautiful, complex, and vital organ. We use human iPS cell-derived organoids, CRISPR gene editing, and high throughput screening to guide development of 21st century therapies.
Current research areas include polycystic kidney disease, cilia, glomerular disease, COVID-19, diabetic kidney disease, nephropathic cystinosis, and kidney regeneration.
The Shankland Lab is dedicated to investigating glomerular disease at the bedside in order to ultimately benefit patients. In particular, we study kidney regeneration, responses to kidney injury in disease, how potential therapies might impact outcomes at a molecular level, and how aging impacts kidney biology.